Track topics on Twitter Track topics that are important to you
Shares of Sesen Bio Inc. (SESN) are up more than 37% over the past 3 days while the iShares Nasdaq Biotechnology Index (ETF)(IBB) has gained a mere 1.2% for the same period.
Eleven Biotherapeutics is rebranding itself as Sesen Bio and investors are pleased. This morning shares of Eleven are up more than 4 percent in premarket trading.
Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasi...
Sesen Bio Inc. (cancer drug development; formerly Eleven Biotherapeutics) netted $36.8mm through a public offering of 22.2mm common shares at $1.80. The funds will support development and commercial-s...
Sesen Bio Inc. (cancer drug development; formerly Eleven Biotherapeutics) netted $42.3mm through a public offering of 25.56mm common shares (including the overallotment) at $1.80. The funds will suppo...
Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that Stephe...
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, tod...
Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the companyâs Targeted Prote...
We have published hundreds of Sesen Bio, Inc. news stories on BioPortfolio along with dozens of Sesen Bio, Inc. Clinical Trials and PubMed Articles about Sesen Bio, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sesen Bio, Inc. Companies in our database. You can also find out about relevant Sesen Bio, Inc. Drugs and Medications on this site too.